02 apr: Investeringsforeningen Multi Manager Invest - forløb af ordinær g..
02 apr: Brøndby IF – konstituering af bestyrelsen
02-04-2019 18:21:31

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Company Announcement

Copenhagen, Denmark; April 2, 2019 –

Genmab A/S (Nasdaq Copenhagen: GEN) will increase its share capital by 146,961 shares as a consequence of the exercise of employee warrants.

The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1:

300 shares at DKK 31.75,

100 shares at DKK 40,41

250 shares at DKK 45.24,

250 shares at DKK 79.25,

54,475 shares at DKK 80.55,

6,250 shares at DKK 147.50,

10,000 shares at DKK 174.00,

11,250 shares at DKK 220.40,

1,000 shares at DKK 225.30,

28,000 shares at DKK 225.90,

1,125 shares at DKK 231.50,

850 shares at DKK 234.00,

31,462 shares at DKK 337.40,

1,174 shares at DKK 466.20,

350 shares at DKK 815.50, and

125 shares at DKK 939.50.

Proceeds to the company are approximately DKK 28.15 million. The increase corresponds to approx. 0.24 % of the company's share capital.

The new shares are ordinary shares without any special rights and are freely transferable negotiable instruments. The new shares give rights to dividends and other rights in relation to the company as of subscription, i.e. inter alia full rights to dividends for the financial year 2019. The new shares will be listed on Nasdaq Copenhagen after registration with the Danish Business Authority. The capital increase is expected to be finalized shortly.

Pursuant to section 32 of the Danish Capital Markets Act No 12 of January 8, 2018, it is hereby announced, that the total nominal value of Genmab A/S' share capital after the capital increase is DKK 61,670,829, which is made up of 61,670,829 shares of a nominal value of DKK 1 each, corresponding to 61,670,829 votes.

About Genmab

Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer.  Founded in 1999, the company has two approved antibodies, DARZALEX® (daratumumab) for the treatment of certain multiple myeloma indications, and Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications.  Daratumumab is in clinical development for additional multiple myeloma indications and other blood cancers.  A subcutaneous formulation of ofatumumab is in development for relapsing multiple sclerosis.  Genmab also has a broad clinical and pre-clinical product pipeline.  Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody® platform for generation of bispecific antibodies, the HexaBody® platform, which creates effector function enhanced antibodies and the HexElect® platform, which combines two co-dependently acting HexaBody molecules to introduce selectivity while maximizing therapeutic potency. The company intends to leverage these technologies to create opportunities for full or co-ownership of future products.  Genmab has alliances with top tier pharmaceutical and biotechnology companies.  For more information visit www.genmab.com.

Contact:          

Marisol Peron, Corporate Vice President, Communications & Investor Relations

T: +1 609 524 0065; E: mmp@genmab.com

For Investor Relations:

Andrew Carlsen, Senior Director, Investor Relations

T: +45 3377 9558; E: acn@genmab.com

This Company Announcement contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com. Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.

Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; DuoBody in combination with the DuoBody logo®; HexaBody®; HexaBody in combination with the HexaBody logo®; DuoHexaBody®; HexElect®; and UniBody®. Arzerra® is a trademark of Novartis AG or its affiliates. DARZALEX® is a trademark of Janssen Pharmaceutica NV.

Company Announcement no. 17

CVR no. 2102 3884

LEI Code 529900MTJPDPE4MHJ122

Genmab A/S

Kalvebod Brygge 43

1560 Copenhagen V

Denmark

Attachment

logo.jpg

Relateret indhold
19 jun - 
Genmab: Blackrock er tilbage i storaktionærklubben
12 jun - 
Genmab/Jyske: Forsinket godkendelse har øget risiko for..
11 jun - 
Tirsdagens aktier: Ambu og Novo toppede marked klædt i ..
Relateret debat
26 jun - 
https://ir.actiniumpharma.com/press-releases/detail/335
26 jun - 
Kunne du virkelig gætte det🙂
26 jun - 
Du virker en anelse utålmodig. Jeg har være..
Del

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
26 jun
GEN
Du virker en anelse utålmodig. Jeg har været med siden børsintroduktionen i 2000, og jeg tager det s..
4
26 jun
GEN
https://ir.actiniumpharma.com/press-releases/detail/335
2
26 jun
GEN
Ja. Det store spørgsmål er tidshorisonten. Men der kan komme nyheder når som helst.Godkendelse. Nye ..
1

Aktier/åbning: Chr. Hansen falder tungt og trækker C25 med ned

27-06-2019 09:10:58
Et stort kursfald til Chr. Hansen præger den danske aktieåbning torsdag, efter at ingredienskoncernen onsdag aften uventet nedjusterede forventningerne til regnskabsåret 2018/19.Efter fem minutters handel er Chr. Hansens aktie faldet 14,7 pct. til 617,20 kr., og det vægter tungt i C25-indekset, som ligger 1 pct. lavere i 1114,21 - dog også efter fald i 15 af de øvrige aktier i indekset.Chr. Hansen..

Citigroup sænker Carlsberg-anbefaling

27-06-2019 07:49:00
Det amerikanske finanshus Citigroup har sænket anbefalingen af Carlsberg-aktien til "sælg".Det skriver Bloomberg News, der dog ikke oplyser, hvordan anbefalingen var tidligere.Citi vurderer i kommentaren, at sårbarheden i Carlsbergs aktiekurs stiger, da momentum i indtjeningen falmer. Finanshuset vurderer også, at der er vejrrelaterede problemer på nøglemarkederne i Europa og stigende konkurrence ..

Lars Christensens Verden - Episode 23: Sådan bruger danskerne deres penge

Relaterede nyheder
26-06-2019 12:10:56
I denne episode af “Lars Christensens Verden” får du svar på, om der er forskel på kvinders og mænds investeringsadfærd, hvorfor unge mænd bruger så mange penge på gambling, og hvorfor kvinder burde investere mere i aktier.Ugens gæst, privatøkonom og senioranalytiker Louise Aggerstrøm Hansen, Danske Bank, deler sine mange indsigter i de private husholdningers økonomiske adfærd, forbrugsmønstre og ..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Aktier/Saxo Bank: Novo Nordisk har været en af eliteindeksets vindere
2
ABG om Ambu: Topchefs køb af aktier sender et godt signal til markedet
3
Aktier/tendens: Chr. Hansen ses i strid modvind fra åbningen
4
Onsdagens aktier: Ambu glimtede i toppen mens Nilfisk blev straffet
5
Trump ser "mulig" handelsaftale på G20

Relaterede aktiekurser

Genmab A/S 1,158.00 -0,9% Fald i aktiekurs

Copyright Berlingske Media 2019  Handelsbetingelser  |  Cookiedeklaration  |  Cookie- og Privatlivspolitik  |  Ophavsret og vilkår
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
27. juni 2019 14:14:06
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20190527.1 - EUROWEB2 - 2019-06-27 14:14:06 - 2019-06-27 14:14:06 - 1 - Website: OKAY